Breast Cancer

Latest News

Data suggest trastuzumab deruxtecan and pertuzumab may represent a new first-line standard of care for metastatic, HER2-positive breast cancer. | Image credit: Axel Kock - stock.adobe.com
Trastuzumab Deruxtecan Plus Pertuzumab Improves PFS vs Standard Care in HER2+ Breast Cancer

June 2nd 2025

Trastuzumab deruxtecan plus pertuzumab demonstrated statistically and clinically significant improvement in progression-free survival (PFS) in HER2-positive breast cancer, potentially representing a new standard of care.

AJMC
Comparing Breast Cancer Treatment Outcomes Between Fee-for-Service and Medicare Advantage

April 4th 2025

Screen-detected breast cancer. | Image Credit: keetazalay - stock.adobe.com
Interval Breast Cancer Risk High Despite Screening, Highlights Need for Risk-Based Approach

March 27th 2025

Diverse women and breast cancer support | Image Credit: ©Atstock Productions-stock.adobe.com
Same-Day Breast Imaging Gaps Reveal Health Care Disparities

February 18th 2025

Pink ribbon for breast cancer | Image Credit: Andrey Popov - stock.adobe.com
Black Patients With Metastatic Triple-Negative Breast Cancer Are Less Likely to Get Immunotherapy, Study Finds

February 17th 2025

Advances in CDK4/6 Inhibitor Use in High-Risk Early Breast Cancer: 2024 Updates

Experts discuss the impact of CDK4/G inhibitor use, including medication cost, total care costs, toxicity profiles, and strategies to manage and optimize patient outcomes in high-risk early breast cancer.

Watch the latest AJMC Peer Exchange on Advances in CDK4/6 Inhibitor Use in High-Risk Early Breast Cancer: 2024 Updates

More News

Group of women
November 19th 2020

Younger, Minority Women With Metastatic Breast Cancer Using More EOL Care

Maggie L. Shaw
Patients younger than 65 years represent close to 40% of deaths from metastatic breast cancer, yet their use of end-of-life (EOL) care has not been thoroughly investigated until now.
Mammography image
November 17th 2020

Women With Dense Breast Tissue May Benefit From Abbreviated Breast MRI

Maggie L. Shaw
Supplemental screening for breast cancer, beyond the standard-of-care mammography, may benefit some women who have dense breast tissue.
HRT Associated With Higher Breast Cancer Risk
November 13th 2020

HRT Associated With Higher Breast Cancer Risk, Study Finds

Rose McNulty
A recent study published in The BMJ suggests that the increased breast cancer risk varies by hormone replacement therapy (HRT) type, but that combined treatments and longer duration might lead to the highest risk.
Bilateral Mastectomy Possibly Linked to Poor Self-Image Among Young Breast Cancer Survivors
November 10th 2020

Bilateral Mastectomy Possibly Linked to Poor Self-Image Among Young Breast Cancer Survivors

Maggie L. Shaw
A recent study of female breast cancer survivors shows that feelings toward body image were consistently worse among those who had a bilateral mastectomy vs breast-conserving surgery.
Elderly woman alone
November 7th 2020

Study Results Point to Possible Survival Link Between Elderly Age, Chemotherapy

Maggie L. Shaw
Having node-positive, estrogen receptor–positive breast cancer indicated a greater likelihood of overall survival following chemotherapy, despite having several comorbidities, after adjustment for confounders.
Breast Cancer Survivor
November 2nd 2020

Black Patients With Breast Cancer May Face Longer Waits, Treatment Duration

Rose McNulty
A recent analysis identified disparities in the start of breast cancer treatment and the duration of treatment in Black women compared with White women.
Aditya Bardia, MBBS, MPH, Massachusetts General Hospital
November 1st 2020

Dr Aditya Bardia: Further Research Is Needed to Understand Resistance to Sacituzumab Govitecan

Despite FDA accelerated approval in April, we still need to learn more about resistance to this antibody drug conjugate, said Aditya Bardia, MBBS, MPH, breast medical oncologist, Massachusetts General Hospital, Harvard Medical School.
Axillary Surgery Approach Impacts BCRL Risk in Breast Cancer Patients
October 28th 2020

Axillary Surgery Approach Impacts BCRL Risk in Breast Cancer Patients

Rose McNulty
A study published in the Journal of Clinical Oncology determined that the main risk factor for breast cancer-related lymphedema in patients with positive axillary lymph nodes is the type of axillary surgery used.
Aditya Bardia, MBBS, MPH, Massachusetts General Hospital
October 25th 2020

Dr Aditya Bardia Forecasts What’s to Come for the ASCENT Trial in Triple-Negative Breast Cancer

Initial preliminary efficacy and safety data are expected sometime next year, stated Aditya Bardia, MBBS, MPH, breast medical oncologist, Massachusetts General Hospital, Harvard Medical School.
This Week in Managed Care for the week of October 19
October 23rd 2020

This Week in Managed Care: October 23, 2020

This week, the top managed care news included COVID-19 delays in breast cancer surgery; targeted therapies associated with decreased mortality risk for non–small cell lung cancer; an inside look at a patient’s perspective of early-onset Parkinson disease.
Breast Cancer Survivor
October 20th 2020

COVID-19 Delays in Breast Cancer Surgery Could Mean More Deaths Over Next Decade

Rose McNulty
A new analysis predicts close to 3000 additional deaths over a 10-year period in patients who faced delays in breast cancer treatment during the pandemic.
Timothy Yap, MBBS, MD Anderson
October 19th 2020

Dr Timothy Yap Reiterates the Unmet Medical Need for Molecularly Targeted Agents in Solid Tumors

Early results on rucaparib/sacituzumab govitecan are promising, but further exploration is needed, stated Timothy A. Yap, MBBS, PhD, FRCP, medical director of the Institute for Applied Cancer Science, MD Anderson Cancer Center.
breast cancer
October 12th 2020

Ductal Carcinoma in Situ Associated With Higher Breast Cancer Death Risk

Rose McNulty
Findings suggest that current standard treatment does not eliminate the risk of breast cancer-specific death in the 20 years after DCIS diagnosis.
Aditya Bardia, MBBS, MPH, Harvard Medical School
October 12th 2020

Dr Aditya Bardia on How Combining Sacituzumab Govitecan, Talazoparib Amplifies Treatment Response

There is a synthetic lethality between sacituzumab govitecan and a PARP inhibitor, noted Aditya Bardia, MBBS, MPH, breast medical oncologist, Massachusetts General Hospital, Harvard Medical School.
Dr Timothy Yap: PARP/TOP1 Inhibitor Toxicities Can Be Managed Through Targeted Delivery
October 5th 2020

Dr Timothy Yap: PARP/TOP1 Inhibitor Toxicities Can Be Managed Through Targeted Delivery

Targeted tumor delivery of irinotecan through sacituzumab govitecan can help to reduce treatment-related toxicities, noted Timothy A. Yap, MBBS, PhD, FRCP, medical director of the Institute for Applied Cancer Science, MD Anderson Cancer Center.
Mortality Higher Among Women With Interval vs Screening-Detected Breast Cancers
October 1st 2020

Mortality Higher Among Women With Interval vs Screening-Detected Breast Cancers

Maggie L. Shaw
Results from a study on Canadian women who did and did not participate in a population-based breast cancer screening program show that interval breast cancers are more aggressive and deadlier than screening-detected cancers.
Dr Aditya Bardia Discusses the Advantages of Sacituzumab Govitecan for Triple-Negative Breast Cancer
September 28th 2020

Dr Aditya Bardia Discusses the Advantages of Sacituzumab Govitecan for Triple-Negative Breast Cancer

There is a clear need for better therapies to treat triple-negative breast cancer, especially when progression-free survival is around 2%, says Aditya Bardia, MBBS, MPH, breast medical oncologist at Massachusetts General Hospital, Harvard Medical School.
Timothy Yap, MBBS, MD Anderson
September 25th 2020

Dr Timothy Yap: Rucaparib/Sacituzumab Govitecan Combo Effective Against Triple-Negative Disease

A novel combination shows promise against advanced solid tumors, including triple-negative breast cancer, noted Timothy A. Yap, MBBS, PhD, FRCP, medical director of the Institute for Applied Cancer Science at MD Anderson Cancer Center.
Aspirin May Have Potential as a Chemopreventive Medication Among African American Women
September 21st 2020

Aspirin May Have Potential as a Chemopreventive Medication Among African American Women

Maggie L. Shaw
Aspirin is a known anti-inflammatory agent, but few studies have investigated its use among African American women to reduce the risk of breast cancer.
Gut Microbiota May Influence pCR in Early-Stage Breast Cancer
September 17th 2020

Gut Microbiota May Influence pCR in Early-Stage Breast Cancer

Maggie L. Shaw
A study out of Scotland has linked levels of 2 short-chain fatty acids in female patients with early-stage breast cancer to pathological complete response (pCR) to neoadjuvant chemotherapy.
Hormone Exposure, Early Puberty May Increase Breast Cancer Risk for Adolescent Girls
September 14th 2020

Hormone Exposure, Early Puberty May Increase Breast Cancer Risk for Adolescent Girls

Maggie L. Shaw
Long-term study results show which mechanisms of early-onset puberty in adolescent girls may predispose them to a greater risk of developing breast cancer.
Possible Link Found Between Breast Cancer Mortality and Childhood Radiation Treatment
September 11th 2020

Possible Link Found Between Breast Cancer Mortality and Childhood Radiation Treatment

Maggie L. Shaw
Study results show that among premenopausal women, adulthood second primary breast cancer may carry with it a 2-fold greater risk of death if they had undergone radiation treatment for cancer as a child or young adult.
Early-Onset Breast Cancer Possibly Linked to Preeclamptic Pregnancy, High Birth Weight
September 6th 2020

Early-Onset Breast Cancer Possibly Linked to Preeclamptic Pregnancy, High Birth Weight

Maggie L. Shaw
With little research on the subject, the investigators sought out a connection between certain perinatal factors and risk of young-onset breast cancer in a sister-matched case-control study.
Outcomes and Future of Clinical Pathways
September 2nd 2020

Outcomes and Future of Clinical Pathways

Adding Multiple in a Class and Measuring Success of Pathways
September 2nd 2020

Adding Multiple in a Class and Measuring Success of Pathways

Development of Clinical Pathways and Patient Characteristics
September 2nd 2020

Development of Clinical Pathways and Patient Characteristics

Adjuvant CDK4/6 Inhibition: When it Will Become Routine
September 2nd 2020

Adjuvant CDK4/6 Inhibition: When it Will Become Routine

Breast Cancer Treatment: How COVID-19 Has Altered Care
September 2nd 2020

Breast Cancer Treatment: How COVID-19 Has Altered Care

The Impact of Patient Preference on Payer Compliance
September 2nd 2020

The Impact of Patient Preference on Payer Compliance

Payer Approval for Frontline Options: Restrictive or Broad?
September 2nd 2020

Payer Approval for Frontline Options: Restrictive or Broad?

<1
...
45678910111213>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo